Cancer & immunology biotech Odyssey embarks with $218M, Gary Glick at helm
Odyssey Therapeutics is the latest startup formed by serial biotech entrepreneur Gary Glick. Odyssey’s destination is oncology and immunology drugs that address novel disease targets, and the biotech now has $218 million in Series A financing to fuel the journey.